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Aims Endothelial dysfunction and plaque formation are features of atherosclerosis. Inhibition of L-type calcium channels or
HMG-CoA pathway improves endothelial function and reduces plaque size. Thus, we investigated in stable coronary
artery disease (CAD) the effects of a calcium antagonist on coronary endothelial function and plaque size.
Methods
and results
In 454 patients undergoing PCI, acetylcholine (10
26 to 10
24 M) was infused in a coronary segment without signiﬁcant
CAD. Changes in coronary diameter were measured and an intravascular ultrasound examination (IVUS) was per-
formed. On top of statin therapy, patients were randomized in a double-blind fashion to placebo or nifedipine
GITS 30–60 mg/day and followed for 18–24 months.
Blood pressure was lower on nifedipine than on placebo by 5.8/2.1 mmHg (P , 0.001) as was total and LDL
cholesterol (4.8 mg/dL; P= 0.495), while HDL was higher (3.6 mg/dL; P = 0.026). In the most constricting segment,
nifedipine reduced vasoconstriction to acetylcholine (14.0% vs. placebo 7.7%; P , 0.0088). The percentage change
in plaque volume with nifedipine and placebo, respectively, was 1.0 and 1.9%, ns.
Conclusion The ENCORE II trial demonstrates in a multi-centre setting that calcium channel blockade with nifedipine for up to
2 years improves coronary endothelial function on top of statin treatment, but did not show an effect of nifedipine on
plaque volume.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Coronary artery disease (CAD) is associated with functional and
structural vascular changes leading to ischaemia and/or plaque
rupture.
1,2 Functional changes of coronary arteries precede
lesion formation and become more pronounced with disease pro-
gression.
3–5Typically, release of endothelial nitric oxide (NO) that
mediates coronary vasomotion is reduced and, in turn, adherence
† This manuscript was assessed and accepted for publication by the previous Editorial Ofﬁce based in Leuven.
* Corresponding author. Tel: þ41 1 255 21 21, Fax: þ41 1 255 42 51, Email: cardiotﬂ@gmx.ch
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.
The online version of this article has been published underanopen accessmodel. Users areentitled to use, reproduce,disseminate,ordisplaythe open accessversionof this article for
non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original
place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be
clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
European Heart Journal (2009) 30, 1590–1597
doi:10.1093/eurheartj/ehp151of monocytes and platelets and subsequently smooth muscle
cell migration and proliferation are increased.
2,3 Endothelial dys-
function occurs as a ‘response to injury’ to oxidized low-density
lipoproteins,
2,6 hypertension,
7–9 increased blood glucose,
10,11
and oxygen-derived free radicals.
12
Treatment modalities able to reverse endothelial dysfunction
might have great clinical implications. Several targets have been con-
sidered, among them the renin–angiotensin system that inactivates
NO via stimulation of NADPH-oxidase and thus the production of
superoxide.
13 ACE-inhibitors improve endothelial function in the
brachial
14 and the coronary circulation.
15,16 Inhibition of HMG-
coenzyme reductase not only reduces cholesterol, but also leads
toprenylation and geranylationofproteinsinvolvedintheregulation
of nitric oxide.
17 In the forearm, circulation statins improve endo-
thelial function in hypercholesterolaemia.
18 In the coronary circula-
tion, the effects of statins are controversial at least after 6 months
of treatment
16,19 suggesting that in patients with stable CAD more
time may be required to improve NO-mediated vasomotion.
Calcium channel blockers may reduce oxidative stress and
improve NO release independent of their effects on L-type
calcium channels.
20,21 In previous studies, nifedipine improved
endothelial function after 6 months;
16 however, the impact on
atherosclerotic plaque formation is uncertain.
We, therefore, investigated in patients with stable CAD under-
going a percutaneous intervention (PCI) the effects of long-acting
nifedipine on coronary endothelial function and plaque formation
over 18–24 months on top of standard therapy, including a statin.
22
Methods
Patients
The ENCORE II (Evaluation of Nifedipine on Coronary Endothelial
Function) Study was a randomized, double-blind, placebo-controlled
study investigating the effect of nifedipine GITS 30 mg/day increased
to 60 mg/day on endothelial vasomotion and atherosclerotic burden
in patients undergoing coronary angiography with or without PCI.
Inclusion criteria were: legal age, left coronary artery segment with
 40% area stenosis (index artery), and no vasodilation of index artery
upon acetylcholine infusion. Patients with at least one segment of the
index artery without vasodilation on acetylcholine (visual inspection)
were eligible. Main exclusion criteria were: myocardial infarction (MI)
within 2 weeks or unstable angina (Braunwald class IIIb troponin posi-
tive), stroke, peripheral revascularization or major surgery within 3
months, uncontrolled diabetes, symptomatic hypotension or uncon-
trolled hypertension, left ventricular ejection fraction ,40%, creatinine
.200 mmol/L, transaminases greater than three times ULN, history of
liveror gastrointestinal diseases, and calcium channel blocker treatment
for .2 months prior to inclusion. ACE-inhibitors or ARBs used .2
months were continued, otherwise theywere not allowed. Participating
sites had approval for thestudyfromtheir Institutional Review Board or
Ethics Committee and patients provided written informed consent.
The ﬁrst patient entered the study in June 1999 and last patient’s last
visit took place in January 2004.
Interventions
Before intervention, cardiovascular drugs were withheld for 24 h
(short acting nitrates for at least 3 h). After coronary angiography
and/or PCI, an infusion catheter was positioned in a proximal
segment of the left anterior descending or circumﬂex coronary
artery with luminal narrowing ,40%. Acetylcholine (Miochol, Ciba
Vision, Basel, Switzerland) was infused at 2 mL/min for 3 min in the fol-
lowing order: (1–3) acetylcholine 0.36, 3.6, and 18 mg/ml; (4) isotonic
saline; and ﬁnally (5) a bolus of 250 mg nitroglycerine was injected. At
the end of each infusion, heart rate and blood pressure were recorded
and angiography performed with non-ionic contrast medium. Finally, an
IVUS examination was made.
Planned treatment duration was 18–24 months. At the end of the
treatment, patients underwent catheterization after withdrawal of
study medication for 2–3 days and other cardiovascular drugs for
24 h as at the baseline study. The X-ray tube and catheter were
placed in identical positions and the IVUS catheter was placed at the
same anatomical landmarks as at baseline. The protocol was then
repeated in the index artery.
Patients were seen in the clinic after 2 weeks, 1, 6, 12, and 18
months. Ambulatory blood pressures were taken with a sphygmoman-
ometer. Clinical chemistry and haematology were analysed centrally
(Institute for Clinical Chemistry, University Hospital of Freiburg,
Germany). Cholesterol was determined enzymatically (CHOD-PAP
method, Roche Diagnostics, Mannheim, Germany). HDL-cholesterol
was determined with a homogenous HDL-C assay (Roche Diagnostics,
Mannheim, Germany), and LDL-cholesterol was calculated using the
Friedewald formula.
Study outcomes
The primary endpoint was the effect of nifedipine compared with
placebo on acetylcholine-induced coronary vascular response at the
highest dose of acetylcholine applied both at baseline and follow-up.
The secondary endpoint was the effect of nifedipine compared with
placebo on the percentage change in plaque volume as assessed by
intravascular ultrasound.
Treatments and randomization
The protocol was designed as a randomized, double-blind, double
dummy study with three treatment arms: cerivastatin 0.2 mg/day, cer-
ivastatin 0.8 mg/day, or cerivastatin 0.8 mg/day plus nifedipine GITS
30–60 mg/day.
22 After 294 patients had been randomized, cerivastatin
was withdrawn from the market due to untoward effects.
23,24 The
study was therefore modiﬁed to continue to investigate the effects
of nifedipine GITS 30–60 mg/day vs. placebo on top of lipid lowering
therapy with a statin according to current guidelines.
25,26 Thus, patients
randomized before withdrawal of cerivastatin who gave informed
consent to continue their participation were continued in their pre-
vious treatment arm minus cerivastatin—resulting in a 2:1 distribution
of the patients on placebo and nifedipine, respectively. New patients
were therefore randomized to placebo or nifedipine on a 1:2 ratio
in order to get balanced samples in the two treatment arms. One
hundred and twenty-three of the originally enrolled patients (42% of
randomized patients) re-entered the study. Another 149 patients
were randomized after restart leading to an evaluable population of
226 patients. The exposure time to nifedipine averaged 622 days
(SD: +82 days; range: 488–853 days).
A pre-prepared randomization list for each centre was generated by
sponsor’s statistician with block size 6 and no stratiﬁcations. Patients
were assigned to next free medication box for their random allocation
to treatment group.
The randomization list was adapted for the re-design of the study.
Patients randomized into the original study and who wanted to con-
tinue kept their allocation number without breaking the randomization
code.
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Angiograms were analysed at a core lab (Cardiology, Medical School,
Hannover, Germany). Readers were blinded to patients’ identity and
to treatment arm. In the index artery 2–7 (mean 3) segments distal to
the infusion catheter were measured using CMS edge-detection algor-
ithm (MEDIS, Leiden, The Netherlands
27). Each segment was identiﬁed
byanatomicallandmarksaccordingtoAHAguidelinestofacilitateidenti-
ﬁcation at follow-up. Mean diameters were measured at baseline and
aftereachacetylcholineandnitroglycerineinfusion.Coronaryresponses
were expressed as percent change from baseline of the
acetylcholine-induced change in mean lumen diameter. The pre-deﬁned
targetsegmentforthemaincomparisonwastheonewiththemostpro-
nounced vasoconstriction at any acetylcholine dose at baseline.
IVUS imaging procedure
The IVUS study was performed after acetylcholine infusions. Intracor-
onary nitroglycerine (0.1–0.2 mg) was given and the IVUS catheter
positioned in the target vessel. Two different IVUS systems were
used: 2.9 F 30 MHz Ultra Cross, Scimed, Boston Scientiﬁc, Sunnyvale,
CA, USA or a 2.9 F 30 MHz Vision Five-64 F/X Endosonics, Rancho
Cordova, CA, USA. In each patient, the same catheter type was
used at baseline and follow-up. The position of the IVUS catheter
was controlled with ﬂuoroscopy. The imaging transducer of the
IVUS catheter was placed distal to a major side branch of the target
vessel and the position was documented. Anatomic orientation was
also guided by spoken comments during the IVUS study. IVUS pullback
was mechanically done at 0.5 mm/s. Images, electrocardiogram, and
comments during the pullback were recorded on S-VHS videotape.
At follow-up, IVUS examinations were repeated to accurately match
the coronary segment recorded at baseline.
Analysis of IVUS images
The tapes were analysed by the core laboratory (D.F.) at Hannover
Medical School, Hannover, Germany according to the clinical
expert consensus documentation standards for the acquisition,
measurement, and reporting of IVUS of the American College of
Cardiology.
28 Experienced investigators blinded to patients’ identity
and treatment allocation reviewed baseline and follow-up images.
C a l i b r a t i o nw a sp e r f o r m e dw i t hg r i dm a r k se n c o d e di nt h e
images. One image per second was analysed. Using computerized
planimetry (TapeMeasure, Indec Inc., Mountain View, CA, USA),
borders of the vessel lumen and of the external elastic membrane
(EEM) were identiﬁed and cross-sectional area (CSA) measured.
Atheroma CSA was calculated by EEM CSA minus lumen CSA
for each image. Total atheroma volume was computed as the
Table 1 Enrolment and ﬂow of patients in the ENCORE II study
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tiplied by segment length. From this, total lumen volume and total
EEM volume were derived. The secondary efﬁcacy parameter,
percent change in atheroma volume after 18–24 months of treat-
ment, was deﬁned as:
%ChangeVolAtheroma ¼ 100
ðVolAtheroma;Follow Up   VolAtheroma;BaselineÞ
VolAtheroma;Baseline
:
Statistical analysis
All patients with a readable baseline and follow-up acetylcholine and/
or IVUS study were eligible for the analysis of primary and/or second-
ary outcome parameters.
A sample size of 60 evaluable patients per treatment group was esti-
mated to have a 90% power to detect a mean difference of 12 percen-
tage points change in acetylcholine-induced vasoconstriction using a
two-tailed t-test with a 0.05 signiﬁcance level assuming a within-group
SD of 20%. Analyses of coronary vasomotion were done by ANCOVA
with treatment and centres as ﬁxed effects and the baseline mea-
surement as covariate. The IVUS data were analysed using the
Mann–Whitney test. The between-centre effect was insigniﬁcant in
all of the performed statistical analyses of outcomes. The group com-
parison of vital signs and lipid values during treatment were done by
t-test. Analyses were performed with SAS, version 9.1. If not otherwise
stated data are presented as mean+SD for intragroup statistics and as
mean difference+SEM for intergroup statistics.
Results
Patient characteristics
Informed consent was given by 454 patients, 443 were randomized
and 437 entered study treatment (Table 1). Patients who entered
placebo and who withdrew prematurely are overrepresented.
This is due to the fact that patients entered before the interruption
were randomized to placebo or nifedipine in a 2:1 ratio and not all
of these gave consent to their continuation in the study after
restart. A total of 226 patients were evaluable for the
intention-to-treat analysis of changes in endothelial function and/
or changes in plaque volume. Reasons for non-evaluability are
given in Table 1. The two treatment groups were well matched
at baseline (Table 2). Also, demographics of patients enrolled
into the original protocol did not differ signiﬁcantly from those
enrolled after restart (data not shown).
Mean values over the treatment period for blood pressure and
lipids are given in Table 3. In the nifedipine group, blood pressure
was lower compared with placebo, whereas heart rate did not
differ. In the nifedipine arm, total cholesterol was lower, HDL
cholesterol higher, and LDL cholesterol lower compared with
placebo. Blood pressure and lipids during follow-up did not differ
in patients enrolled into the original protocol from those in
patients enrolled after restart (data not shown).
Acetylcholine test
At baseline and at follow-up, angiograms from 427 and 214
patients, respectively, were readable. Not all patients received all
three doses of acetylcholine due to early occlusion of the artery
at low doses. Thus, 398 (93%) and 192 (88%) patients at baseline
and follow-up, respectively, got the lowest and the medium dose of
acetylcholine while 311 (72%) and 173 (83%), respectively,
received all three doses of acetylcholine. In the most constricting
coronary segment, acetylcholine at the highest dose that was dis-
pensed at baseline and at follow-up in a patient evoked an
average reduction of vessel lumen diameter of 23.4+16.2% in
the nifedipine group and 24.0+18.1% in the placebo group at
baseline. There was no difference between groups (P= 0.2038).
At follow-up, the change from baseline of the acetylcholine
induced change in mean luminal diameter at the highest dose of
acetylcholine that was infused in a patient at baseline and at
follow-up averaged 13.9+16.5% on nifedipine and 7.7+18% on
placebo. The difference between groups was 6.3% (95% CI: 1.6–
10.9, P= 0.0088; Figure 1 and Table 4).
Intravascular ultrasound
At baseline, mean plaque volume in the target artery of patients
with evaluable IVUS was 140 (101) mm
3 (n: 97) in the nifedipine
arm and 157 (101) mm
3 (n: 96) in the placebo group with no sig-
niﬁcant difference between groups (P= 0.168).
Neither the difference in absolute nor relative changes between
treatments was signiﬁcant (P= 0.84 and 0.66, respectively; Tables 5
and 6).
Adverse events
During acetylcholine infusion, transient ECG changes were
reported in ﬁve (1.1%) patients. In ﬁve (1.1%) patients, diffuse
................................................................................
................................................................................
................................................................................
................................................................................
Table 2 Patient demographics at baseline
Nifedipine Placebo
n 114 112
Gender: males (%) 92 (81%) 93 (83%)
Age (+SD) 59.1 (+8.8) 57.4 (+8.8)
Weight (+SD) 79.0 (+10. 8) 81.0 (+11.5)
BMI 27.3 (+3.4) 27.4 (+3.4)
Smoking
Present 20 (17.5%) 29 (25.7%)
Past 59 (51.8%) 54 (47.8%)
Never 35 (30.7%) 28 (24.8%)
Stopped during study 3 (2.6%) 3 (2.6%)
Alcohol consumption
Abstinent 28 (24.6%) 34 (30.1%)
Light 80 (70.2%) 72 (63.7%)
Moderate 6 (5.3%) 7 (6.2%)
Syst BP, mmHg (+SD) 133 (+19) 132 (+18)
Diast BP, mmHg (+SD) 77 (+10) 78 (+10)
HR 67 (+11) 67 (+10)
Total cholesterol, mg/dL (+SD) 192.3 (+13.6) 199.9 (+11.3)
HDL-Chol., mg/dL (+SD) 39.3 (+13.6) 37.6 (+11.3)
LDL-Chol., mg/dL (+SD) 118.8 (+33) 124.6 (+38)
Triglycerides, mg/dL (+ SD) 159 (+94) 162 (+95)
Priorcoronary interventions, n (%) 48 (42.1%) 28 (25.0%)
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quences, requiring resuscitation in one patient, occurred. One
patient suffered an MI possibly related to acetylcholine.
Five patients died during the screening procedures or study par-
ticipation. One patient with acute coronary syndrome died in
cardiac arrest in the catheterization laboratory, possibly related
to acetylcholine. One patient died the day after an uneventful
intervention, probably due to CAD. Two patients died 5–10
days after the baseline catheterization while on cerivastatin
0.2 mg/day, one suddenly and the other of unknown reason.
One patient died of an unrelated neoplasm.
Peripheral oedema occurred in 20 patients (10.5%) on nifedipine
comparedwiththreepatients(1.2%)onplacebo, causingpremature
withdrawal of three patients on nifedipine and one on placebo.
An increase above ﬁve times ULN was noted for creatinine
phosphokinase (CPK) in four (1.7%) patients on placebo and in
four (2.3%) on nifedipine, for SGOT and/or SGPT in two patients,
one in each group.
A 75-year-old female developed rhabdomyolysis after 3 weeks
on cerivastatin 0.8 mg/day. Medication was stopped and the
patient recovered without sequelae.
Discussion
In this multi-centre trial, we assessed the long-term effects of the
calcium channel blocker nifedipine on endothelial function and
plaque volume in a coronary segment with angiographically
minimal disease and a vasoconstrictor response to acetylcholine.
Nifedipine lowered blood pressure and had minor effects on
lipids, but markedly improved coronary endothelial function with
only a small effect on plaque progression.
In ENCORE I,
16 the so far largest clinical trial investigating endo-
thelial dysfunction in CAD with 250 patients, we have previously
found a pronounced effect of the L-type calcium channel antagon-
ist nifedipine on coronary endothelial function after 6 month, while
the HMG-coenzyme reductase inhibitor cerivastatin had only mar-
ginal effects. The latter ﬁnding was in line with CARATS that used
simvastatin in the same patient population.
19 However, when con-
sidering not just the most constricting segment but all analysed
coronary arteries, there was a signiﬁcant effect of the combination
of nifedipine and cerivastatin compared with placebo in the
ENCORE I trial.
16 Thus, it appeared that in contrast to studies in
the forearm circulation of patients with hypercholesterolaemia,
18
coronary endothelial dysfunction is more difﬁcult to reverse and/
or may require longer treatment periods than in other vascular
beds with little atherosclerosis. Furthermore, based on ENCORE
I and CARATS it remained unclear whether improving endothelial
dysfunction would translate into a reduced atherosclerotic burden
in the coronary circulation.
To that end ENCORE II was designed. Originally, the study
involved three groups of patients, i.e. (i) a low statin dose group
(cerivastatin 0.2 mg/day), (ii) a high statin dose group (cerivastatin
0.8 mg/day), and (iii) a group treated with a combination of high
dose cerivastatin and nifedipine.
22 The withdrawal of cerivastatin
from the market
23,24 forced a redesign of the trial after almost
300 patients had been randomized. It was decided that patients
who consented to continued participation after the redesign
would be restarted on either nifedipine or placebo on top of a
statin according to current guidelines.
25,26 Finally, a robust
patient population exposed to the study drug for a prolonged
period of time, ranging from 488 to 853 days was available for
ﬁnal analysis.
Figure 1 Changeincoronaryvasomotionafteracetylcholineinfu-
sion. The percent change in mean lumen diameter at the highest
comparable dose of acetylcholine at baseline and follow-up
(mean+SD) and the percent change in response (mean+SE).
...............................................................................................................................................................................
Table 3 Blood pressure and lipids: mean values during the follow-up period
Nifedipine Placebo Difference (95% CI)
Systolic BP, mm Hg (+SD) 129.5 (17.0) 135.3 (18.2) 25.8 (210.4 to 21.2) P=0.014
Diastolic BP, mm Hg (+SD) 78.5 (9.3) 80.6 (10.3) 22.1 (24.7 to 0.5) P=0.109
Total cholesterol, mg/dL (+SD) 183.3 (38.0) 187.1 (41.3) 23.8 (214.2 to 6.6) P=0.472
HDL-cholesterol, mg/dL (+SD) 44.4 (14.6) 40.8 (11.3) 3.6 (20.2 to 7.0) P=0.040
LDL-cholesterol, mg/dL (+SD) 104.3 (30.6) 109.1 (33.8) 24.8 (213.3 to 3.7) P=0.233
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2.1 mmHg, very much in line with the ACTION trial.
29 Obviously,
this change may in part account for the reduction in
acetylcholin-induced vasoconstriction.
30 LDL cholesterol was
lower and HDL higher on nifedipine compared to placebo. As
this effect on lipids was not observed in other studies with nifedi-
pine, it could be a play of chance. It is unlikely that these changes
contributed to the improvement in vasomotion since much larger
changes in lipids observed in CARAT
19 and in ENCORE I
16 did not
lead to a signiﬁcant improvement in vasomotion. Other laboratory
parameters were not affected by the treatment.
The primary efﬁcacy parameter of ENCORE II was the percent
difference in the change of mean luminal diameter in response to
acetylcholine after 2 years on placebo or nifedipine. The target
segment was the most constricting coronary segment at baseline.
Study drugs were discontinued before the follow-up study to
assure that long-term and not short-term effects were analysed.
Coronary vasoconstriction induced by acetylcholine averaged
25% at baseline, in line with ENCORE I.
16 When compared with
placebo, nifedipine led to a robust 18% reduction of the paradox-
ical vasoconstriction to acetylcholine no matter whether all
patients or only those enrolled after restart were considered.
Thus, these results conﬁrm the shorter ENCORE I trial and
demonstrate that a controlled release formulation of nifedipine
persistently improves coronary endothelial function up to
2 years. In the ENCORE studies nifedipine in the controlled
release form, GITS, was used. They provide a plasma level with
little variation over 24–36 h as long as the GITS is present in
the GI-tract. However, as soon as the GITS is either empty or
has left the bowel nifedipine is cleared from the plasma with the
normal half life of about 2 h.
31 That is, since the effects on vasomo-
tion in our study were measured 48–72 h after last intake of study
medication, the chronic L-type channel blockade appears to
favourably affect the biology of diseased human coronary arteries.
The improvement in vasomotion may be important for the anti-
ischaemic effects of calcium blockers and their ability to reduce
hospitalizations for CAD.
29
The secondary efﬁcacy parameter of the ENCORE II trial was
the percentage change in atheroma volume after 2 years assessed
by intracoronary ultrasound.
28 At baseline, atheroma volume in the
target artery in all patients averaged 148 mm
3. This is less than in
other trials on atherosclerotic lesions.
32 Indeed, in ENCORE II we
investigated a target artery with less than 40% stenosis. With nife-
dipine progression was less (1.0%) compared with placebo (1.9%)
but the difference was not statistically signiﬁcant. These results are
in line with those seen with amlodipine in CAMELOT.
33 These
ﬁndings conﬁrm that coronary atherosclerosis is essentially pro-
gressive in nature. Thus, although in INTACT
34 which used angio-
graphic criteria nifedipine led to a reduction in new coronary
lesions, ENCORE II as well as CAMELOT using a more sensitive
technique allowing for quantitative measurement of plaque
volume suggest that clinically anti-atherosclerotic effects of
calcium blockers are less pronounced than under experimental
conditions.
35,36 A third efﬁcacy parameter of interest would have
been ﬂow reserve as an index of microvascular dysfunction. It
was measured with the ﬂow wire in the ENCORE I study, but
we could not detect any change in the ﬂow reserve after 6
months treatment despite substantial reduction in lipid levels and
a marked effect of nifedipine on vasomotion (unpublished). For
this reason, we did not do it in the present study.
In summary, the ENCORE II study conﬁrmed pronounced endo-
thelial dysfunction as assessed by acetylcholine in a large patient
population with stable CAD and demonstrates that the L-type
calcium channel blocker nifedipine in a long-acting formulation is
able to persistently improve the functional abnormality but with
no signiﬁcant effect on the progression of plaque volume.
...............................................................................................................................................................................
Table 5 Baseline and absolute change in total atheroma volume (mm
3)
Baseline (mean+ + + + +SD) Follow-up (mean+ + + + +SD) Change, mm
3 (95% CI) P-value for difference between groups
Placebo 157 (101) 157 (99) 20.5 (27.3, 6.4) 0.84
Nifedipine 140 (101) 140 (101) 0.5 (26.5, 7.5)
...............................................................................................................................................................................
Table 4 Baseline and changes in coronary vasomotion after acetylcholine infusion
Baseline (mean+ + + + +SD) Follow-up (mean+ + + + +SD) Change (95% CI) P-value for difference between groups
Placebo 224.0 (18.1) 216.3 (17.0) 7.7 (4.2,11.1) 0.0088
Nifedipine 223.4 ((16.2) 29.5 (11.9) 13.9 (10.7,17.1)
................................................................................
Table 6 Percent change in total atheroma volume
Change, %
(95% CI)
P-value for difference
between groups
Placebo 3.2 (21.9, 8.3) 0.66
Nifedipine 5.0 (21.3, 11.2)
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